Virtu Financial LLC Ultragenyx Pharmaceutical Inc. Transaction History

Virtu Financial LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 19, 2021	SELL	$106.9 - $167.73 $1.52 Million - $2.38 Million	-14,202 Closed	0 $0
Q4 2020 Feb 24, 2021	BUY	$84.4 - $177.39 $1.2 Million - $2.52 Million	14,202 New	14,202 $1.97 Million
Q2 2020 Aug 07, 2020	SELL	$46.91 - $78.22 $352,810 - $588,292	-7,521 Closed	0 $0
Q4 2019 Feb 04, 2020	BUY	$36.08 - $45.83 $271,357 - $344,687	7,521 New	7,521 $321,000
Q2 2019 Aug 13, 2019	SELL	$54.93 - $74.36 $342,158 - $463,188	-6,229 Closed	0 $0
Q1 2019 Apr 12, 2019	BUY	$39.87 - $69.36 $248,350 - $432,043	6,229 New	6,229 $432,000
Q4 2018 Jan 16, 2019	SELL	$38.89 - $77.3 $762,905 - $1.52 Million	-19,617 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$71.81 - $90.15 $1.41 Million - $1.77 Million	19,617 New	19,617 $1.5 Million
Q2 2018 Jul 30, 2018	SELL	$48.54 - $85.31 $179,355 - $315,220	-3,695 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$48.54 - $85.31 $179,355 - $315,220	3,695 New	3,695 $284,000
Q1 2018 May 14, 2018	SELL	$44.33 - $58.52 $326,800 - $431,409	-7,372 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$43.54 - $57.32 $320,976 - $422,563	7,372	7,372 $342,000

326

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.32B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Virtu Financial LLC with notifications on news.